Drugs / gosuranemab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03658135 | Sep 2018 → Dec 2019 | corticobasal syndrome, progressive non-fluent aphasia, tauopathy, traumatic encephalopathy | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 1 | NCT02658916 | Feb 2016 → Mar 2020 | progressive supranuclear palsy | Biogen | Terminated | No outcome recorded |
| Phase 1 | NCT02460094 | Oct 2015 → Oct 2016 | progressive supranuclear palsy | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02294851 | Dec 2014 → Apr 2016 | tauopathy | Biogen | Completed | No outcome recorded |
| Phase 22 trials · 2 missed | ||||||
| Phase 2 | NCT03352557 | May 2018 → Aug 2021 | Alzheimer disease | Biogen | Terminated | Missed primary |
| Phase 2 | NCT03068468 | Jun 2017 → Sep 2019 | progressive supranuclear palsy | Biogen | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-06-16 | Biogen | Results Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease biogen.com ↗
Gosuranemab did not meet its primary efficacy endpoint of change from baseline at week 78 on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) compared to placebo in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease dementia. |
| 2019-12-13 | Biogen | Results Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy biogen.com ↗
Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). |
| 2018-07-18 | Biogen | Results Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC) biogen.com ↗
Anti-Tau Antibody BIIB092 Binds Secreted Tau in Preclinical Models and Alzheimer’s Disease Cerebrospinal Fluid |
All press releases naming this drug 3 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gosuranemab | “Here, we report the results of TANGO ( NCT03352557 ), a randomized, double-blind, placebo-controlled, parallel-group and multiple-dose long-term trial of gosuranemab-a...” PMID 38012285 ↗ Nov 2023 |
| Known as | BIIB092 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02658916 ↗ |
| Known as | BMS-986168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02294851 ↗ |
| Known as | BMS-986168-01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990042 ↗ |
| Known as | IPN-007 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990042 ↗ |
| Action | Inhibit | “Microtubule-associated protein tau inhibitor” CHEMBL3990042 ↗ |
| Modality | Monoclonal antibody | “BIIB092 is a humanised monoclonal antibody” PMID 31122495 ↗ Jun 2019 |
| Route | Intravenous | “BMS-986168 administered by an intravenous infusion” NCT02294851 ↗ |
| Target | MAPT | “Microtubule-associated protein tau inhibitor” CHEMBL3990042 ↗ |